Evermay Wealth Management LLC Cuts Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Evermay Wealth Management LLC decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 16.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,024 shares of the biopharmaceutical company’s stock after selling 2,247 shares during the quarter. Evermay Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $566,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in BMY. Milestone Investment Advisors LLC bought a new position in Bristol-Myers Squibb during the third quarter valued at approximately $27,000. Northwest Financial Advisors bought a new position in Bristol-Myers Squibb during the fourth quarter valued at approximately $27,000. Pacific Capital Wealth Advisors Inc. bought a new position in Bristol-Myers Squibb during the fourth quarter valued at approximately $34,000. Turtle Creek Wealth Advisors LLC bought a new position in Bristol-Myers Squibb during the fourth quarter valued at approximately $40,000. Finally, Wetzel Investment Advisors Inc. bought a new position in Bristol-Myers Squibb during the fourth quarter valued at approximately $40,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research analyst reports. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. BMO Capital Markets decreased their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Price Performance

BMY traded down $0.30 during trading on Friday, hitting $41.24. 17,425,597 shares of the company traded hands, compared to its average volume of 13,919,494. The company has a market cap of $83.60 billion, a PE ratio of -13.30, a P/E/G ratio of 13.96 and a beta of 0.45. The stock’s 50-day simple moving average is $47.80 and its two-hundred day simple moving average is $49.62. Bristol-Myers Squibb has a 1 year low of $41.07 and a 1 year high of $66.46. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. During the same period last year, the company posted $2.05 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 4.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were paid a $0.60 dividend. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.82%. Bristol-Myers Squibb’s payout ratio is currently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.